498 related articles for article (PubMed ID: 24735248)
1. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
2. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
3. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
4. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
5. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
6. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
8. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of doxorubicin-loaded stealth liposomes modified with RGD mimetic and cellular association in vitro].
Xiong XB; Huang Y; Lü WL; Zhang X; Zhang H; Zhang Q
Yao Xue Xue Bao; 2005 Dec; 40(12):1085-90. PubMed ID: 16496670
[TBL] [Abstract][Full Text] [Related]
10. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
12. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
[TBL] [Abstract][Full Text] [Related]
13. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
[TBL] [Abstract][Full Text] [Related]
15. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
16. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
17. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.
Wang JL; Liu YL; Li Y; Dai WB; Guo ZM; Wang ZH; Zhang Q
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):7348-57. PubMed ID: 22977140
[TBL] [Abstract][Full Text] [Related]
18. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
[TBL] [Abstract][Full Text] [Related]
19. iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma.
Zhou JE; Yu J; Gao L; Sun L; Peng T; Wang J; Zhu J; Lu W; Zhang L; Yan Z; Yu L
Mol Pharm; 2017 May; 14(5):1811-1820. PubMed ID: 28388081
[TBL] [Abstract][Full Text] [Related]
20. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y
Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
